Each year I make a list of predictions for the stem cell and regenerative medicine field for the coming new year. Later in this post I list my top 20 stem cell predictions for 2017. In looking at my past predictions I realized this will now be my 7th year doing stem cell/regenerative medicine yearly predictions.
You can see below links to these predictions for past years, which sometimes seems rather far removed from today and in other cases strike me as strangely apropos of our times.
I’ve added a fun and helpful new feature on the right side bar of the blog in the form of a stock ticker for some of the most widely held stem and cellular medicine companies. A sample screen shot is shown in this post.
Quite a few stem cell-related stocks could not be added to this ticker for various reasons including ACTC, Mesoblast, CUR, and others. Yahoo has limits on which stocks can be included based on company size and which exchange they are on.
Think I should have included a different panel of stem cell stocks? Let me know what you think.